<?xml version="1.0" encoding="UTF-8"?>
<p id="Par25" class="p">There is an increasing prevalence of multidrug resistant microorganisms and these bacterial pathogens are a major threat to existing antibacterial therapeutic options [
 <xref ref-type="bibr" rid="CR3" class="xref">3</xref>]. GBS is generally sensitive to Î²-lactams antibiotics but isolates with reduced minimum inhibitory concentrations (MICs) have been described from as far back as 1995 [
 <xref ref-type="bibr" rid="CR1" class="xref">1</xref>] while MIC changes of cefazolin to GBS have been described from 1999 [
 <xref ref-type="bibr" rid="CR2" class="xref">2</xref>]. In a recent study in Italy, outright resistance to GBS was noted for the first time where out of 65 GBS isolates recovered in the study, 12.07% were resistant to benzyl penicillin [
 <xref ref-type="bibr" rid="CR4" class="xref">4</xref>].
</p>
